Skip to main content

A conjoined universal helper epitope can unveil antitumor effects of a neoantigen vaccine targeting an MHC class I-restricted neoepitope.

Publication ,  Journal Article
Swartz, AM; Congdon, KL; Nair, SK; Li, Q-J; Herndon, JE; Suryadevara, CM; Riccione, KA; Archer, GE; Norberg, PK; Sanchez-Perez, LA; Sampson, JH
Published in: NPJ Vaccines
January 18, 2021

Personalized cancer vaccines targeting neoantigens arising from somatic missense mutations are currently being evaluated for the treatment of various cancers due to their potential to elicit a multivalent, tumor-specific immune response. Several cancers express a low number of neoantigens; in these cases, ensuring the immunotherapeutic potential of each neoantigen-derived epitope (neoepitope) is crucial. In this study, we discovered that therapeutic vaccines targeting immunodominant major histocompatibility complex (MHC) I-restricted neoepitopes require a conjoined helper epitope in order to induce a cytotoxic, neoepitope-specific CD8+ T-cell response. Furthermore, we show that the universally immunogenic helper epitope P30 can fulfill this requisite helper function. Remarkably, conjoined P30 was able to unveil immune and antitumor responses to subdominant MHC I-restricted neoepitopes that were, otherwise, poorly immunogenic. Together, these data provide key insights into effective neoantigen vaccine design and demonstrate a translatable strategy using a universal helper epitope that can improve therapeutic responses to MHC I-restricted neoepitopes.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

NPJ Vaccines

DOI

EISSN

2059-0105

Publication Date

January 18, 2021

Volume

6

Issue

1

Start / End Page

12

Location

England

Related Subject Headings

  • 3207 Medical microbiology
  • 3204 Immunology
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Swartz, A. M., Congdon, K. L., Nair, S. K., Li, Q.-J., Herndon, J. E., Suryadevara, C. M., … Sampson, J. H. (2021). A conjoined universal helper epitope can unveil antitumor effects of a neoantigen vaccine targeting an MHC class I-restricted neoepitope. NPJ Vaccines, 6(1), 12. https://doi.org/10.1038/s41541-020-00273-5
Swartz, Adam M., Kendra L. Congdon, Smita K. Nair, Qi-Jing Li, James E. Herndon, Carter M. Suryadevara, Katherine A. Riccione, et al. “A conjoined universal helper epitope can unveil antitumor effects of a neoantigen vaccine targeting an MHC class I-restricted neoepitope.NPJ Vaccines 6, no. 1 (January 18, 2021): 12. https://doi.org/10.1038/s41541-020-00273-5.
Swartz AM, Congdon KL, Nair SK, Li Q-J, Herndon JE, Suryadevara CM, et al. A conjoined universal helper epitope can unveil antitumor effects of a neoantigen vaccine targeting an MHC class I-restricted neoepitope. NPJ Vaccines. 2021 Jan 18;6(1):12.
Swartz, Adam M., et al. “A conjoined universal helper epitope can unveil antitumor effects of a neoantigen vaccine targeting an MHC class I-restricted neoepitope.NPJ Vaccines, vol. 6, no. 1, Jan. 2021, p. 12. Pubmed, doi:10.1038/s41541-020-00273-5.
Swartz AM, Congdon KL, Nair SK, Li Q-J, Herndon JE, Suryadevara CM, Riccione KA, Archer GE, Norberg PK, Sanchez-Perez LA, Sampson JH. A conjoined universal helper epitope can unveil antitumor effects of a neoantigen vaccine targeting an MHC class I-restricted neoepitope. NPJ Vaccines. 2021 Jan 18;6(1):12.

Published In

NPJ Vaccines

DOI

EISSN

2059-0105

Publication Date

January 18, 2021

Volume

6

Issue

1

Start / End Page

12

Location

England

Related Subject Headings

  • 3207 Medical microbiology
  • 3204 Immunology